Last reviewed · How we verify
Micardis®. Observational Study
This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.
Details
| Lead sponsor | Boehringer Ingelheim |
|---|---|
| Status | COMPLETED |
| Enrolment | 4532 |
| Start date | 1999-12 |
Conditions
- Hypertension
Interventions
- Low dose of Telmisartan, once daily
- High dose of Telmisartan, once daily
Primary outcomes
- Changes in systolic and diastolic blood pressure — Baseline, 4 weeks and 3 months after start of treatment
- Percentage of patients with dose titration to 80 mg — 4 weeks and 3 months after start of treatment
- Number of patients with adverse events — Up to 3 months after start of treatment
- Global evaluation of treatment compliance by investigator, a 6-point rating scale — 4 weeks and 3 months after start of treatment